New treatment option for patients with chronic hepatitis C

Patients were divided into three groups. Both would receive the new treatment at varying doses, and the third will receive no treatment. After 24 weeks, the control group was stratified into one of the treatment arms.Finally, 245 patients were treated with 9 mcg CIFN with ribavirin daily, and 242 others took 15 mcg day CIFN with ribavirin. After 24 weeks, patients with HCV RNA were considered non-responders and stopped therapy. Interested parties have continued to take their treatment through week 48 and were followed through week 72.

A new combination therapy of interferon consensus per day and ribavirin is effective for some people chronically infected with hepatitis C virus who do not respond to standard treatment.

For their study, Yaswen and colleagues have worked with human mammary epithelial cells , the cells lining the breast ducts where most breast cancers begin. In a pot of culture, the vast majority of breast cells display a phenotype that allows them to divide between five and 20 times before becoming senescent. However, there are also rare variant HMEC, which have a phenotype that allows them to continue to divide in culture for several weeks.

While adverse events were common, most patients continued treatment in spite of them. Common side effects were neutropenia, fatigue, leukopenia, depression, nausea, muscle pain, lymphopenia and anemia.

A new treatment with the potential to help patients with persistent HCV involves high doses of interferon consensus per day in combination with ribavirin. The researchers, led by Bruce Bacon of St. Louis University, conducted a multicenter study to evaluate the efficacy, tolerability and safety of this approach.

This study has shown that some patients with chronic hepatitis C who have not responded to treatment with PEG-IFN and ribavirin can be successfully removed CIFN daily and RBV, the authors conclude. The rates of sustained virologic response in most reprocessing in the present study was observed in F0-F3 patients who had a partial virologic response during their first treatment.

Almost 7 % of patients treated with 9 mcg of CIBN, and 10.7 % of those treated with 15 mcg, achieved a sustained viral response.

Rates are even higher in patients who had responded to treatment standards and among those who had lower scores reference fibrosis.